Skip to main content

$0.030 (0%)

High

$0.03

Low

$0.03

Trades

25

Turnover

$28,362

Volume

960,646
30 June 2023 at 4:10pm
Register to track LBT and receive email alerts.
Subject
LBT Ann: Company Presentation ASX Small and Mid-Cap Conference

LBT Ann: New Data Published on APAS Technology

LBT Ann: Appendix 4G

LBT Ann: Corporate Governance Statement

LBT Ann: Annual Report to shareholders

LBT Ann: Appendix 4E

LBT Ann: Application for quotation of securities - LBT

LBT Ann: Proposed issue of securities - LBT

LBT Ann: Updated Product Pipeline Strategy Announced

LBT Ann: Notification of cessation of securities - LBT

LBT Ann: Quarterly Activities/Appendix 4C Cash Flow Report

LBT Ann: APAS Independence Showcased at Major US Microbiology Conf

LBT Ann: Direct Sale of APAS Independence in United States

LBT Ann: Quarterly Activities/Appendix 4C Cash Flow Report

LBT Ann: Clinical Data Featuring APAS Technology Presented at ECCMID

LBT Ann: Purchase Order for Multiple APAS Instruments

LBT Ann: Half Yearly Report and Accounts

LBT Ann: LBT Receives $824,500 R&D Tax Incentive

LBT Ann: Quarterly Activities/Appendix 4C Cash Flow Report

LBT Ann: Notification regarding unquoted securities - LBT

LBT Ann: Notification of cessation of securities - LBT

LBT Ann: LBT Investor Call to discuss CCS Acquisition

LBT Ann: LBT Completes CCS Acquisition

LBT Ann: Notice of Initial Substantial Holder

LBT Ann: LBT Completes CCS Acquisition

LBT Ann: Appendix 3Y - Simon Arkell

LBT Ann: Appendix 3Y - Damian Lismore

LBT Ann: Appendix 3Y - Brian O'Dwyer

LBT Ann: Appendix 3Y - Joanne Moss

LBT Ann: Notice under Section 708A - Cleansing Notice

LBT Ann: Notification regarding unquoted securities - LBT

LBT Ann: Application for quotation of securities - LBT

LBT Ann: Update - Proposed issue of securities - LBT

LBT Ann: Notification regarding unquoted securities - LBT

LBT Ann: Notification regarding unquoted securities - LBT

LBT Ann: Application for quotation of securities - LBT

LBT Ann: Proposed issue of securities - LBT

LBT Ann: LBT to Obtain Full Ownership of CCS Joint Venture

LBT Ann: Market Update - Sales Pipeline and Evaluations

LBT Ann: Results of Meeting

LBT Ann: CEO Presentation - AGM 2021

LBT Ann: Chair's Address to Shareholders - AGM 2021

LBT Ann: Jobkeeper Payments Notification

LBT Ann: US FDA 510(k) Clearance for MRSA Analysis Module

LBT Ann: Quarterly Activities/Appendix 4C Cash Flow Report

LBT Ann: Notice of Annual General Meeting/Proxy Form

LBT Ann: Presentation at Australia Biotech Invest & Partnering 2021

LBT Ann: SA Government Extends Loan Repayment Schedule

LBT Ann: Final Director's Interest Notice

LBT Ann: Kate Costello Retires as Director and Chair of the Board

Register to track LBT and receive email alerts.

Similar Companies

AT1
COH
CSX
CYC
EMV
IBX
IPD
MX1
RSH
SOM